JP2024539148A - Ｉｌ－４ｒアンタゴニストを投与することによって結節性痒疹を治療する方法 - Google Patents

Ｉｌ－４ｒアンタゴニストを投与することによって結節性痒疹を治療する方法 Download PDF

Info

Publication number
JP2024539148A
JP2024539148A JP2024523646A JP2024523646A JP2024539148A JP 2024539148 A JP2024539148 A JP 2024539148A JP 2024523646 A JP2024523646 A JP 2024523646A JP 2024523646 A JP2024523646 A JP 2024523646A JP 2024539148 A JP2024539148 A JP 2024539148A
Authority
JP
Japan
Prior art keywords
antibody
subject
antigen
binding fragment
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024523646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539148A5 (cg-RX-API-DMAC10.html
Inventor
エリザベス・ラウズ
ジョン・オマリー
ナイミッシュ・パテル
エリベルト・シュタウディンガー
アシッシュ・バンサル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2024539148A publication Critical patent/JP2024539148A/ja
Publication of JP2024539148A5 publication Critical patent/JP2024539148A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2024523646A 2021-10-20 2022-10-19 Ｉｌ－４ｒアンタゴニストを投与することによって結節性痒疹を治療する方法 Pending JP2024539148A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163257876P 2021-10-20 2021-10-20
US63/257,876 2021-10-20
US202263300492P 2022-01-18 2022-01-18
US63/300,492 2022-01-18
EP22315048.3 2022-03-04
EP22315048 2022-03-04
PCT/US2022/078341 WO2023069976A1 (en) 2021-10-20 2022-10-19 Methods for treating prurigo nodularis by administering an il-4r antagonist

Publications (2)

Publication Number Publication Date
JP2024539148A true JP2024539148A (ja) 2024-10-28
JP2024539148A5 JP2024539148A5 (cg-RX-API-DMAC10.html) 2025-10-27

Family

ID=84329583

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024523646A Pending JP2024539148A (ja) 2021-10-20 2022-10-19 Ｉｌ－４ｒアンタゴニストを投与することによって結節性痒疹を治療する方法

Country Status (10)

Country Link
US (1) US20230183362A1 (cg-RX-API-DMAC10.html)
EP (1) EP4419557A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024539148A (cg-RX-API-DMAC10.html)
KR (1) KR20240099290A (cg-RX-API-DMAC10.html)
CN (1) CN119137149A (cg-RX-API-DMAC10.html)
AU (1) AU2022369296A1 (cg-RX-API-DMAC10.html)
CA (1) CA3235380A1 (cg-RX-API-DMAC10.html)
IL (1) IL312187A (cg-RX-API-DMAC10.html)
MX (1) MX2024004762A (cg-RX-API-DMAC10.html)
WO (1) WO2023069976A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102502640B1 (ko) 2012-08-21 2023-02-23 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
CA3246946A1 (en) 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
KR20220034878A (ko) 2019-07-16 2022-03-18 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
CA2664343C (en) 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
MX366337B (es) 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
EP2823841A1 (en) 2013-07-09 2015-01-14 Sanofi-Aventis Deutschland GmbH Autoinjector
TW201707741A (zh) 2015-06-03 2017-03-01 賽諾菲阿凡提斯德意志有限公司 針頭護罩之抓握器、蓋子、自動注射器及製造抓握器之方法
TW201711716A (zh) 2015-06-03 2017-04-01 賽諾菲阿凡提斯德意志有限公司 護罩鎖
TW201709941A (zh) 2015-06-03 2017-03-16 賽諾菲阿凡提斯德意志有限公司 聲響指示器（二）
TW201707738A (zh) 2015-06-03 2017-03-01 賽諾菲阿凡提斯德意志有限公司 注射器支架及自動注射器（二）
TW201711713A (zh) 2015-06-03 2017-04-01 賽諾菲阿凡提斯德意志有限公司 藥物輸送裝置（五）
CN107474134B (zh) 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
KR102330596B1 (ko) 2018-11-09 2021-11-26 아주대학교산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
CA3161037A1 (en) * 2019-12-09 2021-06-17 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
CN113549151A (zh) 2020-04-24 2021-10-26 苏州康乃德生物医药有限公司 与人IL-4Rα中特定表位结合的抗体及其应用
WO2022052974A1 (en) 2020-09-10 2022-03-17 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing interleukin-4 receptor alpha and uses thereof

Also Published As

Publication number Publication date
AU2022369296A1 (en) 2024-05-30
US20230183362A1 (en) 2023-06-15
KR20240099290A (ko) 2024-06-28
CN119137149A (zh) 2024-12-13
CA3235380A1 (en) 2023-04-27
MX2024004762A (es) 2024-05-08
WO2023069976A1 (en) 2023-04-27
IL312187A (en) 2024-06-01
EP4419557A1 (en) 2024-08-28

Similar Documents

Publication Publication Date Title
US20210322546A1 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
AU2025205430A1 (en) Methods for treating nasal polyposis by administering an IL-4R antagonist
US20230183362A1 (en) Methods for treating prurigo nodularis by administering an il-4r antagonist
US20230146317A1 (en) Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist
CA3296213A1 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
WO2022150605A1 (en) Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
TW202432598A (zh) 藉由投予il-4r拮抗劑治療手足皮膚炎的方法
US20250388685A1 (en) Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist
WO2026059949A1 (en) Methods for treating chronic pruritus of unknown origin (cpuo) by administering an il-4r antagonist
JP2025528456A (ja) Ｉｌ－４ｒアンタゴニストの投与による慢性誘発性寒冷蕁麻疹の治療方法
HK40110800A (en) Methods for treating or preventing asthma by administering an il-4r antagonist
HK40070002A (en) Combination comprising an il-4r antagonist, a corticosteroid and a long-acting beta2-adrenergic agonist for treating asthma
HK40070002B (en) Combination comprising an il-4r antagonist, a corticosteroid and a long-acting beta2-adrenergic agonist for treating asthma
HK1231767B (en) Methods for treating or preventing asthma by administering an il-4r antagonist

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251017